Elanix Biotechnologies AG (FRA:ELN) Net Change in Cash : €-2.07 Mil (TTM As of Dec. 2018)

View and export this data going back to . Start your Free Trial

What is Elanix Biotechnologies AG Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Elanix Biotechnologies AG's Net Change in Cash for the six months ended in Dec. 2018 was €0.00 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2018 was €-2.07 Mil.

Elanix Biotechnologies AG Net Change in Cash Historical Data

The historical data trend for Elanix Biotechnologies AG's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elanix Biotechnologies AG Net Change in Cash Chart

Elanix Biotechnologies AG Annual Data

Trend

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Net Change in Cash

Get a 7-Day Free Trial

0.02

0.05

0.14

-0.19

Elanix Biotechnologies AG Semi-Annual Data
	Dec08	Dec09	Jun10	Dec10	Jun11	Dec11	Jun12	Dec12	Jun13	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18
Net Change in Cash	Get a 7-Day Free Trial															0.19	2.21	-2.07	-	-

Elanix Biotechnologies AG Net Change in Cash Calculation

Elanix Biotechnologies AG's Net Change in Cash for the fiscal year that ended in Dec. 2018 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	-2.551	+	-0.003	+	2.365	+	0
	=	-0.19

Elanix Biotechnologies AG's Net Change in Cash for the quarter that ended in Dec. 2018

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= 0 + 0 + 0 + 0

= 0.00

Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2018 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-2.07 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Elanix Biotechnologies AG Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Elanix Biotechnologies AG's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Elanix Biotechnologies AG (FRA:ELN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Elanix Biotechnologies AG (FRA:ELN) » Definitions » Net Change in Cash

Comparable Companies

XSAT:ACUC XCNQ:VENI BOM:524202 CXUS ETST INNV BOM:524711 BOM:531726 CYIG ASX:AZT BOM:530233 SGX:BFK BUE:ROSE WAR:CBD XCNQ:RQB NSE:PAR BOM:540694 TSXV:GYSR OSTO:GABA XCNQ:GSTR

Traded in Other Exchanges

N/A

Address

Street-4, Georg-Glock, c/o HEUKING KÜHN LÜER WOJTEK, Dusseldorf, NW, DEU, 40474

Website

https://www.elanixbiotechnologies.ch

Elanix Biotechnologies AG is a tissue regeneration company. It develops and commercializes products for acute wound care, dermatological and gynecological applications as well as providing cell technology services. The company's operating segment include Regenerative Medicine and Cosmetic ointments. It generates maximum revenue from the Cosmetic ointments segment. Geographically, it derives a majority of revenue from Switzerland and also has a presence in the EU, and Taiwan.

Elanix Biotechnologies AG (FRA:ELN) Headlines

No Headlines